Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T76937 Target Info
Target Name Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
Synonyms Voltage-gated sodium channel subunit alpha Nav1.3; Voltage-gated sodium channel subtype III; Sodium channel protein, brain III subunit alpha; Sodium channel protein type III subunit alpha; Sodium channel protein type 3 subunit alpha; Sodium channel protein brain III subunit alpha; NAC3; KIAA1356
Target Type Successful Target
Gene Name SCN3A
Biochemical Class Voltage-gated ion channel
UniProt ID
SCN3A_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2013161312
Title Pyrrolopyridinone Derivatives As Ttx-S Blockers.
Abstract The present invention relates to pyrrolopyridinone derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
Applicant(s) Raqualia Pharma Inc
Representative Drug(s) D06VYB Drug Info IC50 = 140 nM Click to Show More [1]
2 D09YJV Drug Info IC50 < 1000 nM [1]
Patent ID WO2010137351
Title Aryl Substituted Carboxamide Derivatives As Calcium or Sodium Channel Blockers.
Abstract The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as NaV1.3 and NaV1.7, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.
Applicant(s) Raqualia Pharma Inc
Representative Drug(s) D0M8WO Drug Info N.A. Click to Show More [1]
2 D0OP5F Drug Info N.A. [1]
Patent ID WO2012020567
Title Acyl Piperazine Derivatives As Ttx-S Blockers.
Abstract The present invention relates to acyl piperazine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
Applicant(s) Raqualia Pharma Inc
Representative Drug(s) D03GPV Drug Info IC50 < 5000 nM [1]
References  Top
REF 1 Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.